You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCandoxatril
Accession NumberDB00616  (APRD00027)
TypeSmall Molecule
GroupsApproved
DescriptionCandoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor used in the treatment of chronic heart failure.
Structure
Thumb
Synonyms
[4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-Indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid
4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylic acid
External Identifiers
  • UK-79,300
  • UK-79300
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIACP75508EE
CAS number123122-55-4
WeightAverage: 515.6383
Monoisotopic: 515.288302671
Chemical FormulaC29H41NO7
InChI KeyInChIKey=ZTWZVMIYIIVABD-OEMFJLHTSA-N
InChI
InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21-,23-,24+/m0/s1
IUPAC Name
(1s,4s)-4-{1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentaneamido}cyclohexane-1-carboxylic acid
SMILES
COCCOC[[email protected]](CC1(CCCC1)C(=O)N[[email protected]]1CC[[email protected]](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassIndanes
Sub ClassNot Available
Direct ParentIndanes
Alternative Parents
Substituents
  • Indane
  • Fatty acid ester
  • Cyclohexylamine
  • Fatty acyl
  • Fatty amide
  • Dicarboxylic acid or derivatives
  • Secondary carboxylic acid amide
  • Carboxylic acid ester
  • Carboxamide group
  • Ether
  • Dialkyl ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of hypertension, improve exercise capacity in patients with CHF receiving angiotensin converting enzyme inhibition.
PharmacodynamicsCandoxatril is the orally-active prodrug of candoxatrilat (UK-73967), the active enantiomer of candoxatrilat (UK-69578), a potent neutral endopeptidase (NEP) inhibitor used in the treatment of chronic heart failure in man.
Mechanism of actionNeutral endopeptidase inhibitors such as Candoxatril have a dual mechanism of action. They inhibit two metalloprotease enzymes, neutral endopeptidase and ACE, resulting in an increased availability of natriuretic peptides that exhibit vasodilatory effects and, possibly, tissue protective effects.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9142
Blood Brain Barrier+0.8437
Caco-2 permeable-0.6787
P-glycoprotein substrateSubstrate0.8158
P-glycoprotein inhibitor INon-inhibitor0.8213
P-glycoprotein inhibitor IINon-inhibitor0.9075
Renal organic cation transporterNon-inhibitor0.7707
CYP450 2C9 substrateNon-substrate0.7497
CYP450 2D6 substrateNon-substrate0.7492
CYP450 3A4 substrateSubstrate0.6952
CYP450 1A2 substrateNon-inhibitor0.7035
CYP450 2C9 inhibitorNon-inhibitor0.7548
CYP450 2D6 inhibitorNon-inhibitor0.8484
CYP450 2C19 inhibitorNon-inhibitor0.6641
CYP450 3A4 inhibitorNon-inhibitor0.9144
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8421
Ames testNon AMES toxic0.62
CarcinogenicityNon-carcinogens0.9494
BiodegradationNot ready biodegradable0.8614
Rat acute toxicity2.5001 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9833
hERG inhibition (predictor II)Non-inhibitor0.5652
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00225 mg/mLALOGPS
logP3.55ALOGPS
logP4.68ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.29ChemAxon
pKa (Strongest Basic)1.32ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area111.16 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity138.16 m3·mol-1ChemAxon
Polarizability57.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Candoxatril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Candoxatril.
AcebutololCandoxatril may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Aceclofenac.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Candoxatril.
AdapaleneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Adapalene.
AlfuzosinAlfuzosin may increase the hypotensive activities of Candoxatril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Candoxatril.
AliskirenCandoxatril may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Candoxatril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Candoxatril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Candoxatril.
AlprenololCandoxatril may increase the hypotensive activities of Alprenolol.
AmbrisentanCandoxatril may increase the hypotensive activities of Ambrisentan.
AmifostineCandoxatril may increase the hypotensive activities of Amifostine.
AmilorideAmiloride may increase the hyperkalemic activities of Candoxatril.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Candoxatril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Candoxatril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Candoxatril.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Candoxatril.
AmlodipineAmlodipine may increase the hypotensive activities of Candoxatril.
AntipyrineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Antipyrine.
ApremilastThe risk or severity of adverse effects can be increased when Candoxatril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Candoxatril.
ArdeparinArdeparin may increase the hyperkalemic activities of Candoxatril.
AtenololAtenolol may increase the hypotensive activities of Candoxatril.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Candoxatril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Candoxatril.
AzapropazoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azapropazone.
AzathioprineCandoxatril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Candoxatril.
BalsalazideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Balsalazide.
BemiparinBemiparin may increase the hyperkalemic activities of Candoxatril.
BenazeprilBenazepril may increase the hypotensive activities of Candoxatril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Candoxatril.
BenmoxinBenmoxin may increase the hypotensive activities of Candoxatril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Benoxaprofen.
BepridilCandoxatril may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Candoxatril.
BethanidineBethanidine may increase the hypotensive activities of Candoxatril.
BimatoprostCandoxatril may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Candoxatril.
BoceprevirThe serum concentration of Candoxatril can be decreased when it is combined with Boceprevir.
BosentanBosentan may increase the hypotensive activities of Candoxatril.
BretyliumCandoxatril may increase the hypotensive activities of Bretylium.
BrimonidineCandoxatril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Candoxatril.
BromfenacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatril.
BumetanideBumetanide may increase the hypotensive activities of Candoxatril.
BupranololCandoxatril may increase the hypotensive activities of Bupranolol.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Candoxatril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Candoxatril.
CandesartanCandoxatril may increase the hypotensive activities of Candesartan.
CaptoprilCandoxatril may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Candoxatril can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Candoxatril.
CarprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Candoxatril.
CarvedilolCandoxatril may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Celecoxib.
CeliprololCandoxatril may increase the hypotensive activities of Celiprolol.
CertoparinCertoparin may increase the hyperkalemic activities of Candoxatril.
ChloroquineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Chloroquine.
ChlorothiazideCandoxatril may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Candoxatril.
CilazaprilCandoxatril may increase the hypotensive activities of Cilazapril.
CiprofloxacinCandoxatril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Candoxatril.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Candoxatril.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Candoxatril.
ClonidineClonidine may increase the hypotensive activities of Candoxatril.
ClonixinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Clonixin.
CryptenamineCandoxatril may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Candoxatril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Candoxatril.
CyclothiazideCyclothiazide may increase the hypotensive activities of Candoxatril.
D-LimoneneThe risk or severity of adverse effects can be increased when Candoxatril is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Candoxatril.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Candoxatril.
DebrisoquinCandoxatril may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Candoxatril.
DeserpidineCandoxatril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Candoxatril.
DiazoxideDiazoxide may increase the hypotensive activities of Candoxatril.
DiclofenacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Diclofenac.
DiflunisalThe risk or severity of adverse effects can be increased when Candoxatril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Candoxatril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Candoxatril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Candoxatril.
DiltiazemDiltiazem may increase the hypotensive activities of Candoxatril.
DorzolamideCandoxatril may increase the hypotensive activities of Dorzolamide.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Candoxatril.
DoxazosinDoxazosin may increase the hypotensive activities of Candoxatril.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Candoxatril.
DrospirenoneCandoxatril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Droxicam.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Candoxatril.
EfonidipineCandoxatril may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Candoxatril.
EnalaprilatCandoxatril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Candoxatril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Candoxatril.
EpirizoleThe risk or severity of adverse effects can be increased when Candoxatril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Candoxatril.
EpoprostenolCandoxatril may increase the hypotensive activities of Epoprostenol.
EprosartanCandoxatril may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Candoxatril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Candoxatril.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Candoxatril.
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Candoxatril.
EtanerceptThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Candoxatril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Candoxatril.
exisulindThe risk or severity of adverse effects can be increased when Candoxatril is combined with exisulind.
FelodipineCandoxatril may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Fenbufen.
FenoldopamCandoxatril may increase the hypotensive activities of Fenoldopam.
FenoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Flurbiprofen.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Candoxatril.
FosinoprilFosinopril may increase the hypotensive activities of Candoxatril.
FurazolidoneFurazolidone may increase the hypotensive activities of Candoxatril.
FurosemideFurosemide may increase the hypotensive activities of Candoxatril.
GarlicThe serum concentration of Candoxatril can be decreased when it is combined with Garlic.
GuanabenzCandoxatril may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Candoxatril.
GuanethidineCandoxatril may increase the hypotensive activities of Guanethidine.
GuanfacineCandoxatril may increase the hypotensive activities of Guanfacine.
HeparinHeparin may increase the hyperkalemic activities of Candoxatril.
HexamethoniumCandoxatril may increase the hypotensive activities of Hexamethonium.
HMPL-004The risk or severity of adverse effects can be increased when Candoxatril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Candoxatril.
HydralazineCandoxatril may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideCandoxatril may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideCandoxatril may increase the hypotensive activities of Hydroflumethiazide.
IbuprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Candoxatril.
IcatibantThe risk or severity of adverse effects can be increased when Candoxatril is combined with Icatibant.
IloprostIloprost may increase the hypotensive activities of Candoxatril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Candoxatril.
IndapamideCandoxatril may increase the hypotensive activities of Indapamide.
IndenololCandoxatril may increase the hypotensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Indoprofen.
IndoraminCandoxatril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Candoxatril.
IproniazidIproniazid may increase the hypotensive activities of Candoxatril.
IrbesartanCandoxatril may increase the hypotensive activities of Irbesartan.
IronThe risk or severity of adverse effects can be increased when Candoxatril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Candoxatril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Candoxatril.
IsoxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Candoxatril.
KebuzoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Candoxatril.
LacidipineCandoxatril may increase the hypotensive activities of Lacidipine.
Lanthanum carbonateThe serum concentration of Candoxatril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostCandoxatril may increase the hypotensive activities of Latanoprost.
LeflunomideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Candoxatril.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Candoxatril.
LisinoprilCandoxatril may increase the hypotensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Candoxatril.
LofexidineCandoxatril may increase the hypotensive activities of Lofexidine.
LornoxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Lornoxicam.
LosartanCandoxatril may increase the hypotensive activities of Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Candoxatril.
LoxoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Lumiracoxib.
MacitentanCandoxatril may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Candoxatril is combined with Magnesium salicylate.
ManidipineCandoxatril may increase the hypotensive activities of Manidipine.
MasoprocolThe risk or severity of adverse effects can be increased when Candoxatril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Candoxatril.
MecamylamineCandoxatril may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Candoxatril.
MetamizoleThe risk or severity of adverse effects can be increased when Candoxatril is combined with Metamizole.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Candoxatril.
MethyldopaCandoxatril may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Candoxatril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Candoxatril.
MetipranololCandoxatril may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Candoxatril.
MetoprololMetoprolol may increase the hypotensive activities of Candoxatril.
MibefradilCandoxatril may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Candoxatril.
MinaprineMinaprine may increase the hypotensive activities of Candoxatril.
MinoxidilMinoxidil may increase the hypotensive activities of Candoxatril.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Candoxatril.
MoclobemideMoclobemide may increase the hypotensive activities of Candoxatril.
MoexiprilCandoxatril may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Candoxatril.
MoxonidineCandoxatril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nabumetone.
NadololCandoxatril may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Candoxatril.
NaftifineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Candoxatril is combined with NCX 4016.
NebivololCandoxatril may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Candoxatril.
NepafenacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Candoxatril.
NicardipineCandoxatril may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hyperkalemic activities of Candoxatril.
NicorandilCandoxatril may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Niflumic Acid.
NiguldipineCandoxatril may increase the hypotensive activities of Niguldipine.
NilvadipineCandoxatril may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Candoxatril.
NisoldipineNisoldipine may increase the hypotensive activities of Candoxatril.
NitrendipineCandoxatril may increase the hypotensive activities of Nitrendipine.
NitroprussideNitroprusside may increase the hypotensive activities of Candoxatril.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Candoxatril.
ObinutuzumabCandoxatril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Candoxatril.
OlmesartanOlmesartan may increase the hypotensive activities of Candoxatril.
OlopatadineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Olsalazine.
OmapatrilatCandoxatril may increase the hypotensive activities of Omapatrilat.
OrgoteinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Oxaprozin.
OxprenololCandoxatril may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Oxyphenbutazone.
ParecoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Parecoxib.
PargylineCandoxatril may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Candoxatril.
PenbutololCandoxatril may increase the hypotensive activities of Penbutolol.
PentoliniumCandoxatril may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Candoxatril.
PerindoprilCandoxatril may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Candoxatril.
PheniprazinePheniprazine may increase the hypotensive activities of Candoxatril.
PhenoxybenzamineCandoxatril may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Candoxatril.
PhentolamineCandoxatril may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Candoxatril.
PinacidilCandoxatril may increase the hypotensive activities of Pinacidil.
PindololCandoxatril may increase the hypotensive activities of Pindolol.
PiretanidePiretanide may increase the hypotensive activities of Candoxatril.
PirfenidoneThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Candoxatril.
PiroxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Candoxatril.
PolythiazideCandoxatril may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Candoxatril.
PregabalinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pregabalin.
PropacetamolThe risk or severity of adverse effects can be increased when Candoxatril is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Candoxatril.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Candoxatril.
PTC299The risk or severity of adverse effects can be increased when Candoxatril is combined with PTC299.
QuinaprilCandoxatril may increase the hypotensive activities of Quinapril.
QuinethazoneQuinethazone may increase the hypotensive activities of Candoxatril.
QuinineQuinine may increase the hypotensive activities of Candoxatril.
RamiprilRamipril may increase the hypotensive activities of Candoxatril.
RasagilineRasagiline may increase the hypotensive activities of Candoxatril.
RemikirenRemikiren may increase the hypotensive activities of Candoxatril.
RescinnamineCandoxatril may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Candoxatril.
ResveratrolThe risk or severity of adverse effects can be increased when Candoxatril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Candoxatril.
RiociguatCandoxatril may increase the hypotensive activities of Riociguat.
RituximabCandoxatril may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Rofecoxib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Candoxatril.
SacubitrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Candoxatril.
SalicylamideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Candoxatril.
SalsalateThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salsalate.
SaprisartanCandoxatril may increase the hypotensive activities of Saprisartan.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Candoxatril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Candoxatril.
SelegilineSelegiline may increase the hypotensive activities of Candoxatril.
SelexipagCandoxatril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Candoxatril is combined with Seratrodast.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Candoxatril.
SildenafilSildenafil may increase the antihypertensive activities of Candoxatril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Candoxatril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Candoxatril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Candoxatril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Candoxatril.
SitaxentanCandoxatril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sodium aurothiomalate.
SpiraprilCandoxatril may increase the hypotensive activities of Spirapril.
SpironolactoneSpironolactone may increase the hyperkalemic activities of Candoxatril.
SRT501The risk or severity of adverse effects can be increased when Candoxatril is combined with SRT501.
St. John's WortThe metabolism of Candoxatril can be increased when combined with St. John's Wort.
SulfasalazineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Candoxatril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Candoxatril.
TadalafilTadalafil may increase the antihypertensive activities of Candoxatril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Candoxatril.
TelmisartanCandoxatril may increase the hypotensive activities of Telmisartan.
TemocaprilCandoxatril may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Candoxatril.
TenoxicamThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Candoxatril is combined with Teriflunomide.
TerlipressinCandoxatril may increase the hypotensive activities of Terlipressin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Candoxatril.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Candoxatril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tiaprofenic acid.
TiboloneCandoxatril may increase the hypotensive activities of Tibolone.
TicrynafenCandoxatril may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Candoxatril.
TinzaparinTinzaparin may increase the hyperkalemic activities of Candoxatril.
TipranavirThe serum concentration of Candoxatril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Candoxatril.
TolazolineCandoxatril may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Candoxatril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Candoxatril.
TorasemideTorasemide may increase the hypotensive activities of Candoxatril.
TrandolaprilTrandolapril may increase the hypotensive activities of Candoxatril.
TranilastThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candoxatril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Candoxatril.
TravoprostTravoprost may increase the hypotensive activities of Candoxatril.
TreprostinilTreprostinil may increase the hypotensive activities of Candoxatril.
TriamtereneTriamterene may increase the hyperkalemic activities of Candoxatril.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Candoxatril.
TrichlormethiazideCandoxatril may increase the hypotensive activities of Trichlormethiazide.
TrimazosinCandoxatril may increase the hypotensive activities of Trimazosin.
TrimethaphanCandoxatril may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Candoxatril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Candoxatril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Candoxatril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Candoxatril.
UnoprostoneCandoxatril may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Candoxatril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Candoxatril.
VardenafilVardenafil may increase the antihypertensive activities of Candoxatril.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Candoxatril.
XylometazolineCandoxatril may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Candoxatril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Candoxatril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Candoxatril.
ZileutonThe risk or severity of adverse effects can be increased when Candoxatril is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Candoxatril is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:8168535). Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond (PubMed:17101991). Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:15283675). Involved in the degradation of at...
Gene Name:
MME
Uniprot ID:
P08473
Molecular Weight:
85513.225 Da
References
  1. O'Connell JE, Jardine AG, Davidson G, Connell JM: Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7. [PubMed:1315825 ]
  2. Elsner D, Muntze A, Kromer EP, Riegger GA: Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol. 1992 Aug 15;70(4):494-8. [PubMed:1386491 ]
  3. Plamboeck A, Holst JJ, Carr RD, Deacon CF: Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005 Sep;48(9):1882-90. Epub 2005 Jul 16. [PubMed:16025254 ]
  4. Sansoe G, Aragno M, Mastrocola R, Cutrin JC, Silvano S, Mengozzi G, Smedile A, Rosina F, Danni O, Rizzetto M: Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis. Am J Physiol Renal Physiol. 2006 Jun;290(6):F1337-43. Epub 2006 Jan 31. [PubMed:16449355 ]
  5. Hirata Y, Suzuki E, Hayakawa H, Matsuoka H, Sugimoto T, Kangawa K, Matsuo H: Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. J Cardiovasc Pharmacol. 1994 Feb;23(2):283-90. [PubMed:7511759 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D: Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol. 2001 Apr;37(4):359-66. [PubMed:11300648 ]
  2. Kostova E, Jovanoska E, Zafirov D, Jakovski K, Maleska V, Slaninka-Miceska M: Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats. Bratisl Lek Listy. 2005;106(12):407-11. [PubMed:16642666 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23